Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat (BI 685509) in Diabetic Nephropathy
NCT03165227Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of avenciguat in diabetic nephropathy (DN) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of patients with drug related Adverse Events at 35 days. Started Oct 2017; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03165227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165227.